A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

Divyalakshmi Bhaskaran, Joshua Savage, Amit Patel, Fiona Collinson, Rhys Mant, Florien Boele, Lucy Brazil, Sara Meade, Peter Buckle, Siân Lax, Lucinda Billingham, Susan C Short, Divyalakshmi Bhaskaran, Joshua Savage, Amit Patel, Fiona Collinson, Rhys Mant, Florien Boele, Lucy Brazil, Sara Meade, Peter Buckle, Siân Lax, Lucinda Billingham, Susan C Short

Abstract

Background: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per year in England. Patients with tumours showing O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation represent around 40% of newly diagnosed GBM. Relapse/tumour recurrence is inevitable. There is no agreed standard treatment for patients with GBM, therefore, it is aimed at delaying further tumour progression and maintaining health-related quality of life (HRQoL). Limited clinical trial data exist using cannabinoids in combination with temozolomide (TMZ) in this setting, but early phase data demonstrate prolonged overall survival compared to TMZ alone, with few additional side effects. Jazz Pharmaceuticals (previously GW Pharma Ltd.) have developed nabiximols (trade name Sativex®), an oromucosal spray containing a blend of cannabis plant extracts, that we aim to assess for preliminary efficacy in patients with recurrent GBM.

Methods: ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to assess cannabinoids in patients with recurrent MGMT methylated GBM who are suitable for treatment with TMZ. Patients who have relapsed ≥ 3 months after completion of initial first-line treatment will be randomised 2:1 to receive either nabiximols or placebo in combination with TMZ. The primary outcome is overall survival time defined as the time in whole days from the date of randomisation to the date of death from any cause. Secondary outcomes include overall survival at 12 months, progression-free survival time, HRQoL (using patient reported outcomes from QLQ-C30, QLQ-BN20 and EQ-5D-5L questionnaires), and adverse events.

Discussion: Patients with recurrent MGMT promoter methylated GBM represent a relatively good prognosis sub-group of patients with GBM. However, their median survival remains poor and, therefore, more effective treatments are needed. The phase II design of this trial was chosen, rather than phase III, due to the lack of data currently available on cannabinoid efficacy in this setting. A randomised, double-blind, placebo-controlled trial will ensure an unbiased robust evaluation of the treatment and will allow potential expansion of recruitment into a phase III trial should the emerging phase II results warrant this development.

Trial registration: ISRCTN: 11460478.

Clinicaltrials: Gov: NCT05629702.

Keywords: Adverse events; Brain cancer; Cannabinoids; Glioblastoma; Nabiximols; Overall survival; Progression free survival; Randomised phase II trial; Sativex; Temozolomide; Tumour.

Conflict of interest statement

JS, AP, FC, FB, LBr, PB LBi, and SCS received research funding from The Brain Tumour Charity and were provided with the nabiximols and matched placebo free of charge by Jazz Pharmaceuticals for this study. FC received an honorarium from Bayer. No other authors have any completing interests to declare.

© 2024. The Author(s).

Figures

Fig. 1
Fig. 1
ARISTOCRAT trial schema Overview of ARISTOCRAT trial GBM: Glioblastoma; MGMT: O6-Methylguanine-DNA-methyltransferase

References

    1. Brodbelt A, Greenberg D, Winters T et al. Glioblastoma in England: 2007–2011. European journal of cancer (Oxford, England: 1990). 2015;51(4):533– 42. 10.1016/j.ejca.2014.12.014.
    1. Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden–and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241–5. doi: 10.1038/sj.bjc.6602321.
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005;352(10):987–96. doi: 10.1056/NEJMoa043330.
    1. Leone A, Colamaria A, Fochi NP, et al. Recurrent Glioblastoma treatment: state of the art and future perspectives in the Precision Medicine Era. Biomedicines. 2022;10(8):1927. doi: 10.3390/biomedicines10081927.
    1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi: 10.1056/NEJMoa043331.
    1. Weller M, Tabatabai G, Kästner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21(9):2057–64. doi: 10.1158/1078-0432.Ccr-14-2737.
    1. Limam S, Missaoui N, Abdessayed N et al. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme. Ann Biol Clin. 2019;77(3):307– 17.
    1. Pinson H, Hallaert G, Van der Meulen J et al. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Journal of Neuro-Oncology. 2020;146(1):55–62.
    1. Maroon J, Bost J. Review of the neurological benefits of phytocannabinoids. Surg Neurol Int. 2018;9:91. doi: 10.4103/sni.sni_45_18.
    1. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–25. doi: 10.1016/j.biopsych.2015.07.028.
    1. Ellert-Miklaszewska A, Ciechomska I, Kaminska B. Cannabinoid signaling in glioma cells. Adv Exp Med Biol. 2013;986:209–20. doi: 10.1007/978-94-007-4719-7_11.
    1. Rocha FC, Dos Santos Junior JG, Stefano SC, et al. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. 2014;116(1):11–24. doi: 10.1007/s11060-013-1277-1.
    1. Dumitru CA, Sandalcioglu IE, Karsak M. Cannabinoids in Glioblastoma Therapy: New Applications for Old drugs. Front Mol Neurosci. 2018;11:159. doi: 10.3389/fnmol.2018.00159.
    1. Torres S, Lorente M, Rodríguez-Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90–103. doi: 10.1158/1535-7163.Mct-10-0688.
    1. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197–203. doi: 10.1038/sj.bjc.6603236.
    1. Twelves C, Sabel M, Checketts D, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379–87. doi: 10.1038/s41416-021-01259-3.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Watts C, Savage J, Patel A, et al. Protocol for the Tessa Jowell BRAIN MATRIX platform study. BMJ Open. 2022;12(9):e067123. doi: 10.1136/bmjopen-2022-067123.
    1. Fayers P, Bottomley A. Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer. 2002;38:125–33. doi: 10.1016/S0959-8049(01)00448-8.
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for Use in International clinical trials in Oncology. JNCI: J Natl Cancer Inst. 1993;85(5):365–76. doi: 10.1093/jnci/85.5.365.
    1. Osoba D, Aaronson N, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Research. 1996;5(1):139– 50. DOI.
    1. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033–40. doi: 10.1016/j.ejca.2010.01.012.
    1. Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of life research. 2011;20(10):1727-36. DOI.
    1. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–53. doi: 10.1016/s1470-2045(14)70314-6.
    1. National Cancer Institute Common Terminology Criteria for Adverse Events. (CTCAE) v5.0 2017 [Available from: . Last Accessed: 08-Nov-2022.
    1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J cancer (Oxford England: 1990) 2012;48(14):2192–202. doi: 10.1016/j.ejca.2012.04.011.
    1. Berrocal A, Perez Segura P, Gil M, et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J Neurooncol. 2010;96(3):417–22. doi: 10.1007/s11060-009-9980-7.
    1. Nagane M. Dose-dense temozolomide: is it still promising? Neurologia medico-chirurgica. 2015;55(1):38–49. doi: 10.2176/nmc.ra.2014-0277.
    1. Pharma GW. Sativex Oromucosal Spray SmPC [Summary of Product Characteristics]. electronic medicines compendium (emc); 2022 [Available from: . Last Accessed: 13/07/2022.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться